
【Introduction】
Product Name: Human VEGFR2 / KDR / CD309 Antibody (Vulinacimab, Research Use)
Catalog Number: NBR-0939
Target Name: VEGFR2 / KDR / CD309
Trade Name: Vulinacimab
Antibody Drug Description: Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells.
【Description】
Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS:N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG
【Gene Information】
Gene Name: KDR
Synonyms: CD309; FLK1; VEGFR; VEGFR2
Target Description: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis.
Ensembl: ENSG00000128052
Uniprot: P35968